Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
2003 2
2004 5
2005 5
2006 1
2007 2
2011 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Identification and characterization of novel antagonists of the CCR3 receptor.
Warrior U, McKeegan EM, Rottinghaus SM, Garcia L, Traphagen L, Grayson G, Komater V, McNally T, Helfrich R, Harris RR, Bell RL, Burns DJ. Warrior U, et al. Among authors: komater v. J Biomol Screen. 2003 Jun;8(3):324-31. doi: 10.1177/1087057103008003010. J Biomol Screen. 2003. PMID: 12857386
Selective H3 receptor (H3R) blockade: broad efficacy in cognition and schizophrenia.
Fox GB, Esbenshade TA, Pan JB, Browman KE, Zhang M, Ballard ME, Radek RJ, Miner H, Bitner RS, Krueger KM, Yao BB, Faghih R, Rueter LE, Komater VA, Drescher KU, Buckley MJ, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Fox GB, et al. Among authors: komater va. Inflamm Res. 2005 Apr;54 Suppl 1:S23-4. doi: 10.1007/s00011-004-0410-1. Inflamm Res. 2005. PMID: 15928819 No abstract available.
Potentiation of analgesic efficacy but not side effects: co-administration of an α4β2 neuronal nicotinic acetylcholine receptor agonist and its positive allosteric modulator in experimental models of pain in rats.
Zhu CZ, Chin CL, Rustay NR, Zhong C, Mikusa J, Chandran P, Salyers A, Gomez E, Simler G, Lewis LG, Gauvin D, Baker S, Pai M, Tovcimak A, Brown J, Komater V, Fox GB, Decker MW, Jacobson PB, Gopalakrishnan M, Lee CH, Honore P. Zhu CZ, et al. Among authors: komater v. Biochem Pharmacol. 2011 Oct 15;82(8):967-76. doi: 10.1016/j.bcp.2011.05.007. Epub 2011 May 17. Biochem Pharmacol. 2011. PMID: 21620806
ABT-963 [2-(3,4-difluoro-phenyl)-4-(3-hydroxy-3-methyl-butoxy)-5-(4-methanesulfonyl-phenyl)-2H-pyridazin-3-one], a highly potent and selective disubstituted pyridazinone cyclooxgenase-2 inhibitor.
Harris RR, Black L, Surapaneni S, Kolasa T, Majest S, Namovic MT, Grayson G, Komater V, Wilcox D, King L, Marsh K, Jarvis MF, Nuss M, Nellans H, Pruesser L, Reinhart GA, Cox B, Jacobson P, Stewart A, Coghlan M, Carter G, Bell RL. Harris RR, et al. Among authors: komater v. J Pharmacol Exp Ther. 2004 Dec;311(3):904-12. doi: 10.1124/jpet.104.070052. Epub 2004 Jul 26. J Pharmacol Exp Ther. 2004. PMID: 15277581
Preclinical profiling and safety studies of ABT-769: a compound with potential for broad-spectrum antiepileptic activity.
Giardina WJ, Dart MJ, Harris RR, Bitner RS, Radek RJ, Fox GB, Chemburkar SR, Marsh KC, Waring JF, Hui JY, Chen J, Curzon P, Grayson GK, Komater VA, Ku Y, Lockwood M, Miner HM, Nikkel AL, Pan JB, Pu YM, Wang L, Bennani Y, Durmuller N, Jolly R, Roux S, Sullivan JP, Decker MW. Giardina WJ, et al. Among authors: komater va. Epilepsia. 2005 Sep;46(9):1349-61. doi: 10.1111/j.1528-1167.2005.02905.x. Epilepsia. 2005. PMID: 16146429 Free article.
Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist.
Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA. Fox GB, et al. Among authors: komater va. J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. doi: 10.1124/jpet.104.078402. Epub 2004 Dec 17. J Pharmacol Exp Ther. 2005. PMID: 15608077
15 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page